Analytical challenges and technical limitations in assessing circulating MiRNAs

Anna Zampetaki; Manuel Mayr

doi:10.1160/TH12-02-0097

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2012; 108(04): 592-598
DOI: 10.1160/TH12-02-0097

Theme Issue Article

Schattauer GmbH

Analytical challenges and technical limitations in assessing circulating MiRNAs

Authors

Anna Zampetaki

¹King’s British Heart Foundation Centre, King’s College London, London, UK
Manuel Mayr

¹King’s British Heart Foundation Centre, King’s College London, London, UK

Abstract

Summary

MiRNAs are emerging as promising biomarkers in cardiovascular diseases and may constitute a novel mechanism of intercellular communication. Accurate quantification of circulating miRNAs is essential. A variety of technological approaches and platforms have been developed with increased sensitivity and specificity for the detection and quantification of circulating miRNAs. In this review, we focus on the technical aspects and discuss the analytical challenges in profiling circulating miRNAs.

Keywords

microRNA - biomarker - cardiovascular - diabetes

Full Text

References

References
1 Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
2 Lee Y, Ahn C, Han J. et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003; 425: 415-419.
3 Denli AM, Tops BB, Plasterk RH. et al. Processing of primary microRNAs by the Microprocessor complex. Nature 2004; 432: 231-235.
4 Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
5 Guo H, Ingolia NT, Weissman JS. et al. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466: 835-840.
6 Zampetaki A, Mayr M. MicroRNAs in Vascular and Metabolic Disease. Circ Res 2012; 110: 508-522.
7 Zampetaki A, Willeit P, Drozdov I. et al. Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res 2012; 93: 555-562.
8 Mitchell PS, Parkin RK, Kroh EM. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518.
9 Zernecke A, Bidzhekov K, Noels H. et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009; 02: ra81.
10 Skog J, Wurdinger T, van Rijn S. et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature Cell Biol 2008; 10: 1470-1476.
11 Pegtel DM, Cosmopoulos K, Thorley-Lawson DA. et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA 2010; 107: 6328-6333.
12 Arroyo JD, Chevillet JR, Kroh EM. et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108: 5003-5008.
13 Wang K, Zhang S, Weber J. et al. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res 2010; 38: 7248-7259.
14 Vickers KC, Palmisano BT, Shoucri BM. et al. MicroRNAs are transported in plasma and delivered to recipient cells by highdensity lipoproteins. Nature Cell Biol 2011; 13: 423-433.
15 Kirschner MB, Kao SC, Edelman JJ. et al. Haemolysis during sample preparation alters microRNA content of plasma. PloS One 2011; 06: e24145.
16 Duttagupta R, Jiang R, Gollub J. et al. Impact of Cellular miRNAs on Circulating miRNA Biomarker Signatures. PloS One 2011; 06: e20769.
17 McDonald JS, Milosevic D, Reddi HV. et al. Analysis of Circulating MicroRNA: Preanalytical and Analytical Challenges. Clin Chem 2011; 57: 833-840.
18 George JN, Thoi LL, McManus LM. et al. Isolation of human platelet membrane microparticles from plasma and serum. Blood 1982; 60: 834-840.
19 Garcia ME, Blanco JL, Caballero J. et al. Anticoagulants interfere with PCR used to diagnose invasive aspergillosis. J Clin Microbiol 2002; 40: 1567-1568.
20 Willems M, Moshage H, Nevens F. et al. Plasma collected from heparinized blood is not suitable for HCV-RNA detection by conventional RT-PCR assay. J Virol Methods 1993; 42: 127-130.
21 Cui W, Ma J, Wang Y. et al. Plasma miRNA as biomarkers for assessment of totalbody radiation exposure dosimetry. PloS One 2011; 06: e22988.
22 Gilad S, Meiri E, Yogev Y. et al. Serum microRNAs are promising novel biomarkers. PloS One 2008; 03: e3148.
23 Rio DC, Ares Jr M, Hannon GJ. et al. Purification of RNA using TRIzol (TRI reagent). Cold Spring Harbor Prot 2010. 2010 pdb prot5439.
24 Zampetaki A, Kiechl S, Drozdov I. et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 107: 810-817.
25 Fichtlscherer S, De Rosa S, Fox H. et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010; 107: 677-684.
26 Andreasen D, Fog JU, Biggs W. et al. Improved microRNA quantification in total RNA from clinical samples. Methods 2010; 50: S6-9.
27 Turchinovich A, Weiz L, Langheinz A. et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011; 39: 7223-7233.
28 Ozsolak F, Milos PM. RNA sequencing: advances, challenges and opportunities. Nature Rev Genet 2011; 12: 87-98.
29 Chen X, Ba Y, Ma L. et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
30 Ach RA, Wang H, Curry B. Measuring microRNAs: comparisons of microarray and quantitative PCR measurements, and of different total RNA prep methods. BMC Biotechnol 2008; 08: 69.
31 Raymond CK, Roberts BS, Garrett-Engele P. et al. Simple, quantitative primer-extension PCR assay for direct monitoring of microRNAs and short-interfering RNAs. RNA 2005; 11: 1737-1744.
32 Pradervand S, Weber J, Lemoine F. et al. Concordance among digital gene expression, microarrays, and qPCR when measuring differential expression of microRNAs. BioTechniques 2010; 48: 219-222.
33 Jensen SG, Lamy P, Rasmussen MH. et al. Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs. BMC Genomics 2011; 12: 435.
34 Ansorge WJ. Next-generation DNA sequencing techniques. New Biotechnol 2009; 25: 195-203.
35 Creighton CJ, Reid JG, Gunaratne PH. Expression profiling of microRNAs by deep sequencing. Briefings Bioinformatics 2009; 10: 490-497.
36 Yin JQ, Zhao RC, Morris KV. Profiling microRNA expression with microarrays. Trends Biotechnol 2008; 26: 70-76.
37 Bargaje R, Hariharan M, Scaria V. et al. Consensus miRNA expression profiles derived from interplatform normalization of microarray data. RNA 2010; 16: 16-25.
38 Shingara J, Keiger K, Shelton J. et al. An optimized isolation and labeling platform for accurate microRNA expression profiling. RNA 2005; 11: 1461-1470.
39 Wang H, Ach RA, Curry B. Direct and sensitive miRNA profiling from low-input total RNA. RNA 2007; 13: 151-159.
40 Chen TS, Lai RC, Lee MM. et al. Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. Nucleic Acids Res 2010; 38: 215-224.
41 Sah S, McCall MN, Eveleigh D. et al. Performance evaluation of commercial miRNA expression array platforms. BMC Res Notes 2010; 03: 80.
42 Wang K, Zhang S, Marzolf B. et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009; 106: 4402-4407.
43 Castoldi M, Schmidt S, Benes V. et al. A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA). RNA 2006; 12: 913-920.
44 Castoldi M, Schmidt S, Benes V. et al. miChip: an array-based method for microRNA expression profiling using locked nucleic acid capture probes. Nature Protocols 2008; 03: 321-329.
45 Li S, Zhu J, Zhang W. et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation 2011; 124: 175-184.
46 Chen J, Lozach J, Garcia EW. et al. Highly sensitive and specific microRNA expression profiling using BeadArray technology. Nucleic Acids Res 2008; 36: e87.
47 Lu J, Getz G, Miska EA. et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
48 Jay C, Nemunaitis J, Chen P. et al. miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol 2007; 26: 293-300.
49 Liu CG, Calin GA, Volinia S. et al. MicroRNA expression profiling using microarrays. Nature Protocols 2008; 03: 563-578.
50 Tijsen AJ, Creemers EE, Moerland PD. et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res 2010; 106: 1035-1039.
51 Vorwerk S, Ganter K, Cheng Y. et al. Microfluidic-based enzymatic on-chip labeling of miRNAs. New Biotechnol 2008; 25: 142-149.
52 Chen Y, Gelfond JA, McManus LM. et al. Reproducibility of quantitative RT-PCR array in miRNA expression profiling and comparison with microarray analysis. BMC Genomics 2009; 10: 407.
53 Chen C, Ridzon DA, Broomer AJ. et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33: e179.
54 Mestdagh P, Feys T, Bernard N. et al. High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. Nucleic Acids Res 2008; 36: e143.
55 Linsen SE, de Wit E, Janssens G. et al. Limitations and possibilities of small RNA digital gene expression profiling. Nature Methods 2009; 06: 474-476.
56 Bryant RJ, Pawlowski T, Catto JW. et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012; 106: 768-774.
57 Ballantyne KN, van Oorschot RA, Mitchell RJ. Locked nucleic acids in PCR primers increase sensitivity and performance. Genomics 2008; 91: 301-305.
58 Latorra D, Arar K, Hurley JM. Design considerations and effects of LNA in PCR primers. Mol Cell Probes 2003; 17: 253-259.
59 Levin JD, Fiala D, Samala MF. et al. Position-dependent effects of locked nucleic acid (LNA) on DNA sequencing and PCR primers. Nucleic Acids Res 2006; 34: e142.
60 D'Alessandra Y, Devanna P, Limana F. et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 2010; 31: 2765-2773.
61 Ji X, Takahashi R, Hiura Y. et al. Plasma miR-208 as a biomarker of myocardial injury. Clin Chem 2009; 55: 1944-1949.
62 Zhang Y, Liu D, Chen X. et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 2010; 39: 133-144.
63 Zampetaki A, Willeit P, Tilling L. et al. Prospective Study on Circulating MicroRNAs and Risk of Myocardial Infarction. JACC. 2012 in press.